Centanafadine

Brand names: Simtriyo · Active ingredient: Centanafadine Hydrochloride

In short: SIMTRIYO is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years of age and older weighing at least 20 kg. Limitations of Use The use of SIMTRIYO is not recommended in pediatric patients: Younger than 6 years of age because this pedi

Forms & strengthsExtended-release capsules: 140 mg of centanafadine: capsules with light orange opaque cap (imprinted with "C140") and white opaque body (imprinted with "Otsuka") 210 mg of centanafadine: capsules with yellow opaque cap (imprinted with "C210") and white opaque …
LabelOtsuka America Pharmaceutical, Inc.
Label updatedOct 26, 2026

What is Centanafadine used for?

SIMTRIYO is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years of age and older weighing at least 20 kg.

Limitations of Use

The use of SIMTRIYO is not recommended in pediatric patients:

Younger than 6 years of age because this pediatric subpopulation had a higher incidence of weight loss than pediatric patients 6 years of age and older .

Weighing less than 20 kg because of a lack of data for this subpopulation and the risk of weight loss .

âš  Boxed warning (FDA's strongest warning)

Suicidal Ideation and Behaviors in Pediatric Patients 6 Years of Age and Older

In a short-term (6-week) clinical study, higher rates of suicidal ideation and behavior were reported in SIMTRIYO-treated pediatric patients with attention deficit/hyperactivity disorder (ADHD) aged 6 to 12 years than in pediatric patients treated with placebo. All pediatric patients 6 years of age or older treated with SIMTRIYO should be monitored closely for suicidal ideation and behaviors, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy. Families and caregivers should be advised of the need for close observation and communication with the healthcare provider. Consider stopping SIMTRIYO in patients who experience emergent suicidal ideation and behavior .

Abuse, Misuse, and Addiction

SIMTRIYO has a potential for abuse and misuse. Abuse of central nervous system (CNS) stimulants, including SIMTRIYO, can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including SIMTRIYO, can result in overdose and death , and this risk is increased with a higher dosage or unapproved methods of administration, such as snorting or injection.

Before prescribing SIMTRIYO, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of SIMTRIYO, and proper disposal of any unused drug. …

Centanafadine dosage

Prior to treating patients with SIMTRIYO, assess:

The risk of abuse, misuse, and addiction .

For the presence of cardiac disease (e.g., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) .

Heart rate and blood pressure .

The risk factors for developing a manic episode (e.g., history of depressive symptoms or a family history of suicide, bipolar disorder, or depression) .

For a family history of tics or Tourette' syndrome and clinically evaluate patients for motor or verbal tics or Tourette's syndrome .

Pediatric Patients 6 Years of Age and Older Weighing at Least 20 kg

In pediatric patients 6 to 12 years of age weighing at least 20 kg, the recommended SIMTRIYO dosage is based on weight and is provided in Table 1.

Body Weight (kg) | Dose (mg)

20 kg to less than 35 kg | 140 mg

35 kg to 50 kg | 210 mg

Greater than 50 kg | 280 mg

In pediatric patients 13 to 17 years of age weighing at least 20 kg, the recommended SIMTRIYO dosage is 280 mg orally once daily.

The effectiveness of SIMTRIYO 140 mg once daily in patients aged 13 to 17 years and the weight-based equivalent dosage in patients aged 6 to 12 years was not established . SIMTRIYO 210 mg once daily and weight-based equivalent dosages have not been studied in pediatric patients aged 6 to 17 years and are not recommended.

Adults

In adults, the recommended starting dosage of SIMTRIYO is 210 mg orally once daily. The dosage may be increased to the maximum recommended dosage of 280 mg once daily based on clinical response and tolerability.

Administer SIMTRIYO orally, in the morning, with or without food, at approximately the same time each day . Do not cut, crush, or chew the capsules.

Take SIMTRIYO capsules whole or open the capsule and sprinkle the entire contents over one tablespoon (15 mL) of applesauce or yogurt or in one tablespoon (15 mL) of orange juice. Consume immediately followed by water. Do not chew the granules. Do not save for later use.

Must wait at least 14 days after stopping a monoamine oxidase inhibitor (MAOI) before starting SIMTRIYO .

If a dose of SIMTRIYO is missed, administer the missed dose as soon as remembered but no later than 4 hours after the normal dosing time. Patients should not take more than one dose of SIMTRIYO in the same day.

How to take Centanafadine — instructions & advice from the label

Advise patients or caregivers to read the FDA-approved patient labeling (Medication Guide).

Suicidal Ideation and Behaviors

Patients, their families, and their caregivers should be alerted about the need to monitor patients for the emergence of suicidal ideation and behavior, especially during the first few months of SIMTRIYO treatment. Such symptoms should be reported to the patient's healthcare provider immediately .

Abuse, Misuse, and Addiction

Educate patients and their families about the risks of abuse, misuse, and addiction of SIMTRIYO, which can lead to overdose and death, and proper disposal of any unused drug. Advise patients to store SIMTRIYO in a safe place, preferably locked, and instruct patients to not give SIMTRIYO to anyone else .

Risks to Patients with Serious Cardiac Disease

Advise patients and their caregivers that there are potential risks to patients with serious cardiac disease, including sudden death, with SIMTRIYO use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease . …

Warnings & precautions

Do not take this medicine if: SIMTRIYO is contraindicated in patients:

With known hypersensitivity to centanafadine or any of the excipients of SIMTRIYO. Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported with SIMTRIYO .

Taking, or within 14 days of stopping, MAOIs due to the risk of serious and possibly fatal drug interactions, including hypertensive crisis and serotonin syndrome .

With pheochromocytoma or a history of pheochromocytoma. Serious reactions, including elevated blood pressure and tachyarrhythmia, have been reported in patients with pheochromocytoma or a history of pheochromocytoma who received a CNS stimulant.

In a short-term (6-week) clinical study, higher rates of suicidal ideation and behaviors were reported in SIMTRIYO-treated pediatric patients aged 6 to 12 years of age with ADHD than in placebo-treated pediatric patients .

All pediatric patients 6 years of age and older treated with SIMTRIYO should be monitored closely for suicidal ideation and behavior, clinical worsening, or unusual changes in behavior, especially during the initial months of SIMTRIYO therapy.

Families and caregivers of pediatric patients 6 years of age and older treated with SIMTRIYO should be advised of the need to monitor patients for the emergence of suicidal ideation and behavior, and to report such symptoms immediately to a healthcare provider.

Consider changing the therapeutic regimen, including stopping SIMTRIYO, in patients who experience emergent suicidal ideation or behavior or symptoms that might be precursors to emerging suicidal ideation and behavior, especially if these symptoms are severe or abrupt in onset, or were not part of the patient's presenting symptoms.

SIMTRIYO has a potential for abuse and misuse. …

Centanafadine side effects

The following adverse reactions are discussed in more detail in other sections of the labeling:

Suicidal Ideation and Behaviors in Pediatric Patients Aged 6 Years and Older

Abuse, Misuse, and Addiction

Risks to Patients with Serious Cardiac Disease

Increased Blood Pressure and Heart Rate

Psychiatric Adverse Reactions

Hypersensitivity Reactions

Long-Term Suppression of Growth in Pediatric Patients

Peripheral Vasculopathy Including Raynaud's Phenomenon

Serotonin Syndrome

Motor and Verbal Tics, and Worsening of Tourette's Syndrome

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of SIMTRIYO is based on studies in:

Pediatric patients aged 4 to 17 years with ADHD who were exposed to one or more doses of SIMTRIYO in two 6-week randomized, double-blind, placebo-controlled studies (Studies 1 and 2) and a long-term open-label study. SIMTRIYO is not approved for use in patients less than 6 years of age or weighing less than 20 kg . In Studies 1 and 2, 608 pediatric patients 6 years of age and older were exposed to SIMTRIYO. A total of 394 pediatric patients 6 years of age and older were treated with SIMTRIYO for at least 6 months, and 286 were treated for 12 months or longer. …

Drug interactions

Table 5 presents clinically significant drug interactions with SIMTRIYO.

Monoamine Oxidase Inhibitors (MAOIs)

Prevention or Management | Concomitant use of SIMTRIYO with MAOIs or within 14 days after discontinuing an MAOI is contraindicated .

Mechanism and Clinical Effect(s) | Concomitant use of SIMTRIYO with MAOIs increases the risk of hypertensive crisis (potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure) and serotonin syndrome .

Alcohol

Prevention or Management | Avoid consumption of alcohol at the same time as, and for at least two hours after, administration of SIMTRIYO.

Mechanism and Clinical Effect(s) | Consumption of alcohol at the same time as, and for at least two hours after, administration of SIMTRIYO may result in a more rapid release of centanafadine. A more rapid release of centanafadine may increase exposure-related adverse reactions and may also reduce efficacy during the late hours of the dosing interval due to lower centanafadine exposures .

CYP1A2 Substrates

Prevention or Management | When SIMTRIYO is used concomitantly with CYP1A2 substrates, monitor for adverse reactions and consider dosage reduction of the concomitantly used CYP1A2 substrate. …

About this medicine

SIMTRIYO is a norepinephrine-dopamine-serotonin reuptake inhibitor and central nervous system stimulant. Centanafadine hydrochloride has the chemical designation of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride. The molecular formula is C15H15N∙HCl which corresponds to a molecular weight of 245.75 with the following structural formula:

SIMTRIYO (centanafadine) extended-release capsules for oral use contain 140 mg, 210 mg, or 280 mg of centanafadine, equivalent to 164.4 mg, 246.6 mg, or 328.8 mg, respectively, of centanafadine hydrochloride. Each capsule contains a combination of immediate release, extended release, and delayed release beads. Inactive ingredients for the beads include: colloidal silicon dioxide, ethyl acrylate and methyl methacrylate copolymer, hypromellose, mannitol, microcrystalline cellulose, plasacryl, poly (methyl acrylate-CO-methyl methacrylate-CO-methacrylic acid), polysorbate 80, and talc. The capsule shell contains: hypromellose, titanium dioxide, FD&C Blue No. 1 (280 mg capsule), FD&C Yellow No. 5 (210 mg capsule), FD&C Yellow No. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ecfa41cc-c8c8-419b-8da3-ee5b819398c2. Read the full official label on DailyMed.

Related medicines

Tirzepatide Methylphenidate Lisdexamfetamine Amphetamine Orlistat Serdexmethylphenidate and Dexmethylphenidate Benzphetamine Phendimetrazine